D iagnostic test accuracy (DTA) studies are key to evaluating any diagnostic test (symptom, sign, investigation) used in clinical medicine. DTA studies generally present results in terms of paired measures derived from numbers of patients cross-classified by the test and a reference standard in a 2x2 table (Figure 1 ) as true positive (TP), false positive (FP), false negative (FN) and true negative (TN). These paired measures are sensitivity and specificity; positive and negative predictive values (PPV, NPV); and sometimes the positive and negative likelihood ratios (LR+, LR-). 1 Although sensitivity, specificity, and predictive values are familiar to most clinicians, they may be difficult to interpret and apply to individual patients. No absolute criteria for desirable or acceptable values for these parameters are agreed, in part because they depend on the chosen test cut-off value. The once-held belief that sensitivity and specificity were fundamental and constant measures of the intrinsic accuracy of a test is now known not to be the case, as different values may be found in different patient populations.
In addition to paired values, a number of single (unpaired), or unitary, or global measures may be calculated from the outcomes of DTA studies (see Table 1 for examples). All of these metrics have their shortcomings and limitations, and although some are potentially remediable (eg use of partial area under the receiver operating characteristic curve) these are not easy to calculate, nor particularly intuitive.
Thus it may be argued that DTA studies are 'underparameterised' with respect to global or unitary metrics. This has prompted the generation of novel metrics with which to characterise DTA study results: the likelihood to diagnose or misdiagnose (LDM), the summary utility index (SUI) and the number needed for screening utility (NNSU).
Likelihood to diagnose or misdiagnose
The 'number needed to treat' (NNT) metric was developed as a way to represent the 'impact' of treatments, calculated as the reciprocal (or multiplicative inverse) of the absolute risk reduction. 2, 3 This was thought to be more intuitive for clinicians and patients than more traditional measures, low values of NNT being desirable, ideally NNT=1 (ie everybody responds). A 'number needed to harm' (NNH) reflecting the adverse effect of treatments has also been developed, 4 high values of NNH being desirable (ie few patients experience harm).
Citrome and Ketter combined these two measures, NNT and NNH, as a ratio, NNH/NNT, which they called the 'likelihood to be helped or harmed' (LHH). 5 This simple metric gives an indication of the potential risk and benefit for any treatment, and has been adopted in some spheres of medicine. 6 Analogous to LHH for randomised controlled treatment trials, the 'likelihood to be diagnosed or misdiagnosed' (LDM) metric was developed for use in DTA studies. 7 This is calculated as the ratio of the 'number needed to misdiagnose' (NNM) and either the 'number needed to diagnose' (NND) or the 'number needed to predict' (NNP) (see Table 2 for calculation methods). In any DTA study, NNM will be desirably high (ie few patients misdiagnosed) while NND and NNP will be desirably small (ideally = 1, ie everybody New unitary metrics for dementia test accuracy studies
Diagnostic test accuracy studies generally present results in terms of the sensitivity, specificity, and predictive values of the test being examined. Although these metrics are familiar, they may be difficult to interpret and apply to individual patients. This article briefly presents some new easily calculated unitary metrics and compares them for some commonly used cognitive screening instruments and neurological signs used to assess cognitive status, highlighting the underlying weakness or 'fragility' of these tests. would suggest a test more likely to diagnose than misdiagnose, with LDM desirably >>1. LDM has been calculated for some 'non-canonical' neurological signs (ie useful heuristics that are not currently described in standard textbooks of neurology) used in the assessment of cognitive status based on individual studies ( 11 and Ascertain Dementia 8 [AD8] 12 ) using data from individual studies performed in a secondary care setting (Tables 4 and 5) 13, 14 as well as from meta-analyses. 14, 15 As shown in Table 3 , most non-canonical neurological signs had LDM values around 1, with the best results for the head turning sign for diagnosis of any cognitive i m p a i r m e n t a n d t h e a p p l a u s e s i g n f o r diagnosis of dementia. For cognitive screening instruments, it was a surprise to see that LDM values for MoCA and MACE were worse than for MMSE and 6CIT for diagnosis of dementia (Table 4 ) and mild cognitive impairment (Table 5) , since the former tests were designed at least in part to overcome some of the perceived shortcomings of MMSE. The explanation is that both MoCA and MACE are very sensitive tests (as is AD8), and hence generate many false positives, thus deflating NNM. Moreover, they have relatively poor specificity, thus inflating NND and NNP. This combination results in a low LDM value. Admittedly MoCA did better when basing LDM calculation on data from meta-analyses, 15 but the latter may include data from studies in which MoCA is compared with healthy control groups, a less demanding differentiation than pragmatic individual studies. 1 The best overall LDM result for diagnosis of dementia (Table 4 ) was with 6CIT, a test originally designed for use in primary care, 11 which was found to have relatively good balance between sensitivity (0.88) and specificity (0.78) in the secondary care study on which the LDM data are based. 16 The best overall LDM result for diagnosis of mild cognitive impairment (MCI) was with MACE. 10 Summary utility index (SUI) and number needed for screening utility (NNSU) Mitchell proposed a 'clinical utility index' (CUI). Paired measures were defined as CUI+ = sensitivity x PPV, and CUI-= specificity x NPV (Figure 1) , and classified qualitatively (Table 6 ). These paired measures may be used as markers to rule in (CUI+) and rule out (CUI-) the suspected diagnosis. 17 Could a global 'Summary utility index' (SUI) be derived from CUI values, analogous to Y derived from sensitivity and specificity and to PSI derived from predictive values (see definitions of both Y and PSI in Table 1 )? SUI might be given by some kind of summation, but clearly not by a ratio as this would give the relative of value of the test for ruling in or ruling out a diagnosis. Exploring different methods, 18, 19 SUI was defined as the sum of (CUI+ + CUI-), as for the 'gain in certainty' unitary measure derived from sensitivity and specificity. 20 Hence SUI may range from 0 to 2, and is desirably as close to 2 as possible. Using the classification of CUIs suggested by Mitchell, 17 it follows that SUI values might also be qualitatively classified ( Table 6 ).
The reciprocal (multiplicative inverse) of SUI was suggested as the 'number needed for screening utility' No cognitive impairment 0.09 [7] 0.51 [7] 0.48 (very poor) [7] 2.08 (poor)
Abbreviations: LDM = likelihood to be diagnosed or misdiagnosed; NNM = number needed to misdiagnose; NND = number needed to diagnose; NNP = number needed to predict; SUI = summary utility index; CUI = clinical utility index; NNSU = number needed for screening utility (NNSU), ranging between infinity (no screening value for ruling in or ruling out diagnosis) and 0.5 (perfect screening utility for ruling in and ruling out diagnosis), with low values of NNSU desirable (Table 6 ). 18 SUI and NNSU have been calculated for non-canonical neurological signs used in the assessment of cognitive status (Table 3 ) and for various cognitive screening instruments using data from individual studies (Tables 4 and 5 ). 18 As shown in Table 3 , most non-canonical neurological signs had SUI and NNSU values around 1, with the best results for the head turning sign for diagnosis of any cognitive impairment and the applause sign for diagnosis of dementia (rankings essentially as for LDM).
As shown in Table 4 , the cognitive screening instrument achieving the best values for SUI and NNSU (around unity) for dementia diagnosis was 6CIT, as for LDM. As shown in Table 5 , the best values for SUI and NNSU (around unity) for MCI diagnosis were achieved by MACE, again as for LDM.
Discussion
One response to the studies of LDM and SUI and NNSU has been to question whether new parameters are required, when others are already to hand. Of course, these new metrics have shortcomings, including the fact that they depend on the chosen test cut-off (like sensitivity, specificity, predictive values, etc). However, as argued above, available global or unitary test measures have their own shortcomings (Table 1) , and the new metrics avoid some of these. For example, they do take into account TN (cf F measure, AUC ROC, which do not) and do not treat FN and FP as equally undesirable (cf accuracy, net reclassification improvement, identification index, Youden index, DOR). It may be that, unlike existing global measures, they do have intuitive appeal.
Whether one takes a frequentist (emphasis on frequencies or proportions within the sample data) or Bayesian (subjectivist) approach to DTA study outcomes, a common difficulty is in communicating these outcomes to other clinicians and to patients in an easily intelligible manner. Building LDM and NNSU around established 'number needed to' approaches 2,3 hopefully generates more intuitive metrics. Moreover, these measures are easy to calculate from readily available DTA study data (a simple calculator for the purpose, has been designed; Dr JC Williamson, personal communication).
For example, considering the utility of LDM, if a patient is told that a diagnostic test is five times more likely to diagnose than misdiagnose her/his suspected condition (ie LDM = 5), patient willingness to undergo such a test may be greater than if LDM were 1. Likewise, considering utility of SUI and NNSU, patients may feel more inclined to consent to tests with SUI >1, and NNSU ≤1 (ie only one patient needs to be screened for test utility).
For the cognitive screening instruments examined, the proximity of LDM values to unity suggests an underlying weakness in these tests, which might be termed 'fragility'. This presumably reflects the tradeoff between test sensitivity and specificity, between the rule-in and rule-out functions of tests. These findings may relate to the particular individual studies that were analysed, as some instruments achieved better LDM metrics using data extracted from meta-analyses. 14, 15 The SUI and NNSU data were perhaps a little more encouraging (the qualitative rankings of SUI and NNSU may perhaps be too stringent), with values close to unity. Nevertheless, a search for better cognitive screening instruments, optimising LDM, SUI, and NNSU metrics, would seem reasonable.
As for any new test or treatment, a broadening of clinician literacy and familiarity would be required for routine use of LDM, SUI, and NNSU metrics. Considering their simplicity this would present little challenge, and their ease of communication to patients might also act as a powerful advocate for their adoption.
Conclusion
LDM, SUI and NNSU may answer some of the shortcomings of existing unitary, single or global test accuracy metrics. They are intuitive, easy to calculate, interpret and apply to individual patients, and may be used for DTA studies in any field of medicine.
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